Principal Technologies (FRA:JO7) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:JO7 Principal Technologies Inc FRA:JO7
14 GF Score
Price €0.20
GF Value €0.04
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Principal Technologies FFO per Share?

FFO per Share only applies to REITs.

FRA:JO7
14GF Score
Principal Technologies Inc FRA:JO7
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Principal Technologies (FRA:JO7) Overvalued in 2026?

Based on GuruFocus' analysis, Principal Technologies stock appears to be overvalued. The current stock price of €0.20 is trading 393.8% above its estimated GF Value™ of €0.04. GuruFocus considers Principal Technologies to be Significantly Overvalued.

Key valuation signals for FRA:JO7:

  • FFO per Share:
  • GF Value™: €0.04 vs. price of €0.20 (393.8% above fair value)
  • GF Score™: 14/100 with 7 warning signs

No single metric tells the full story. See the FRA:JO7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Principal Technologies Business Description

Other Exchanges PTEC:Canada
Address 700 West Georgia Street, Suite 2500, Vancouver, BC, CAN, V7Y 1B3
Principal Technologies Inc is in the research and development stage of building a portfolio of medical technology assets with a focus on distribution potential and intellectual property capable of enhancing medical treatment, cost efficiency, and optimization of the patient pathway. The company focuses on acquiring medical technology research and development assets or developing them jointly with industry leaders. Its current revenue-generating activities are attributable to E&E CRO Consulting GmbH, which provides clinical research advisory services. The company operates in one reportable operational segment, consisting of project management of clinical studies and research related to medical device technologies.
14GF Score

Get the complete analysis for FRA:JO7

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price
€0.04
GF Value